| 12 |
Impact of Ischemic vs. Bleeding Endpoints: Lessons from ACUITY and HORIZONS |
Roxana Mehran |
Jul. 21. 09 |
| 11 |
Perspectives on the Use of Fondaparinux in ACS: Transitioning to the Cath Lab |
Ron Waksman |
Jul. 21. 09 |
| 10 |
MULTI-STRATEGY: Tirofiban vs. Abciximab During Primary PCI in STEMI |
Marco Valgimigli |
Jul. 21. 09 |
| 9 |
ON-TIME-2: Early Administration of Tirofiban During Primary PCI in STEMI |
Harry Suryapranata |
Jul. 21. 09 |
| 8 |
Direct Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High Risk PCI |
Charles A. Simonton |
Nov. 02. 07 |
| 7 |
Bivalirudin for the Best Overall Outcomes and Most Cath Lab Compatible |
Gregg W. Stone |
Nov. 02. 07 |
| 6 |
Pushing the Envelope for Bivalirudin Monotherapy: Design, Rationale, and Status of ISARREACT-4 and HORIZONS |
Adnan Kastrati |
Nov. 02. 07 |
| 5 |
Taking the Evidence-Based Approach to ACS: Examination of New Antithrombin Trial Data |
Gregg W. Stone |
Sep. 14. 07 |
| 4 |
Direct Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High Risk PCI |
Charles A. Simonton |
Sep. 14. 07 |
| 3 |
Bivalirudin on Trial: Rationale and Status of ISAR-REACT 3 and 4 |
Adnan Kastrati |
Sep. 14. 07 |
